Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy

Laia Paré, David Paez, Juliana Salazar, Elisabeth Del Rio, Eduardo Tizzano, Eugenio Marcuello, Montserrat Baiget

    Research output: Contribution to journalArticleResearchpeer-review

    12 Citations (Scopus)

    Abstract

    AIMS To study the relationship between the toxicity associated with a 5-FU-based therapy and the presence of (i) the large intragenic rearrangements in the DPYD gene and (ii) the IVS14+1G>A mutation. METHODS We used the multiplex ligation-dependent probe amplification technique (MLPA) to study genomic DNA from 234 colorectal cancer patients treated with 5-FU-based chemotherapy. RESULTS We did not detect any deletion/duplication in the DPYD gene. The presence of the IVS14+1G>A mutation was also excluded. CONCLUSIONS Neither the large genomic rearrangements in the DPYD gene nor the IVS14+1G>A mutation play a significant role in the development of serious toxicity associated with a 5-FU containing regimen. © 2010 The British Pharmacological Society.
    Original languageEnglish
    Pages (from-to)268-272
    JournalBritish Journal of Clinical Pharmacology
    Volume70
    Issue number2
    DOIs
    Publication statusPublished - 1 Aug 2010

    Keywords

    • 5-FU
    • Dihydropyrimidine dehydrogenase gene
    • Multiplex ligation-dependent probe amplification (MLPA)

    Fingerprint

    Dive into the research topics of 'Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy'. Together they form a unique fingerprint.

    Cite this